[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100393517":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":68,"collaborators":70,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":10,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},{"fullName":5,"class":6},"Richmond Pharmacology Limited","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trial Participants",null,"Male and female participants aged 5-70 years",[13,14,15],"Diagnostic Test: Membrane-based immunoassay kit","Diagnostic Test: Quantitative antibody Tests","Diagnostic Test: PCR Test",[17,24,30],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DIAGNOSTIC_TEST","Membrane-based immunoassay kit","The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.",[9],[23],"Covid-19 Rapid Test Kit",{"type":18,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Quantitative antibody Tests","Antibody titres will be measured from whole blood samples taken from volunteers.",[9],[29],"Antibody titre",{"type":18,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"PCR Test","PCR tests will be conducted on throat swabs taken from volunteers.",[9],[35],{"name":36,"affiliation":5,"role":37},"Jorg Taubel, MD","PRINCIPAL_INVESTIGATOR",[39,43],{"name":36,"role":40,"phone":41,"phoneExt":10,"email":42},"CONTACT","+44(0)2070425800","j.taubel@richmondpharmacology.com",{"name":44,"role":40,"phone":45,"phoneExt":10,"email":46},"Ulrike Lorch, MD","+44(0)2038482005","u.lorch@richmondpharmacology.com",[48],{"facility":49,"status":50,"city":51,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge","RECRUITING","London","SE1 1YR","United Kingdom","UK",{"type":56,"coordinates":57},"Point",[58,59],-0.12574,51.50853,{"lat":59,"lon":58},[62,66],{"name":63,"role":40,"phone":64,"phoneExt":10,"email":65},"James Rickard","02070425800","j.rickard@richmondpharmacology.com",{"name":67,"role":37,"phone":10,"phoneExt":10,"email":10},"Jorg Taubel, MD FFPM",{"type":69,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[71],{"name":5,"class":6},"100393517","serological-and-pcr-testing-for-covid-19-100393517",false,"NCT04404062","Serological and PCR Testing for COVID-19","Serological and PCR Testing for SARS-CoV-2. A Prospective Study Assessing Infection, Immunity, and Asymptomatic Carriage of COVID-19","Inclusion Criteria:\n\n* Male or female aged 5 to 70 years.\n* An understanding, ability, and willingness to fully comply with the project procedures and restrictions.\n\nExclusion Criteria:\n\n* Not applicable.",true,"ALL","5 Years","70 Years",{"count":84,"type":85},2500,"ESTIMATED","OBSERVATIONAL","Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results. Infection with coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. RRI are currently carrying out the following tests:\n\nA. Using a membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens helps to assess whether an individual has previously had the virus and is potentially immune\n\nB. Polymerase Chain Reaction (PCR) testing using an established method to check for active SARS-CoV-2 infections.\n\nC. Quantification of anti-SARS-CoV-2 IgG and IgM antibodies in whole blood samples.\n\nThe above tests are being used by RRI to follow infections (PCR) and immunity (IgG) in their workforce, as well as their families (including children) and visitors to their site.\n\nCollecting this data allows the gathering of epidemiological data on SARS-CoV-2 including incidence, prevalence, information on asymptomatic carriers and efficacy of vaccination. Furthermore, identifying individuals that are infected with SARS-CoV-2 has great potential to improve health outcomes by allowing infected individuals to seek the correct medical treatment as well as self-isolate and reduce transmission.",[89],"COVID-19","2026-06-15",{"date":92,"type":93},"2026-06-17","ACTUAL",{"date":95,"type":93},"2020-03-16",{"date":97,"type":85},"2028-12",{"name":99,"class":6},"Richmond Research Institute",1]